Figure 2.

TWEAK serum concentrations are decreased in patients with pancreatic cancer but are independent of the disease stage. (A) Serum TWEAK concentrations were measured in patients with pancreatic cancer and healthy blood donors as controls; (B–F) TWEAK levels were unaltered in patients with different T-status, nodal positive vs. negative disease, metastasized vs. non-metastasized disease, R0 and R1 resected patients, and different tumor gradings; (E) TWEAK levels were unaltered in patients with R0 vs. R1 resection; (G) ROC curve analysis comparing the diagnostic value of TWEAK and CA19-9 for pancreatic cancer.